尊龙凯时

关于尊龙凯时
研发效劳
效劳平台
客户中心
新闻资讯
投资者关系
人力资源
EN
×
EN

  • 营业咨询

    中国：

    Email: marketing@medicilon.com.cn

    营业咨询专线：400-780-8018

    （仅限效劳咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    外洋：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心
Jun 28,2023
GS-5801是一种高效KDM5抑制剂，具有抗HBV活性，本研究中GS-5801通过尊龙凯时合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
审查更多
GS-5801是一种高效KDM5抑制剂，具有抗HBV活性，本研究中GS-5801通过尊龙凯时合成
Jun 28,2023
QF-036是一种高效的HIV-1抑制剂，具有优异的和药代动力学特征，PK研究通过尊龙凯时举行
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
审查更多
QF-036是一种高效的HIV-1抑制剂，具有优异的和药代动力学特征，PK研究通过尊龙凯时举行
Jun 28,2023
设计合成一种新型选择性的口服有用苏氨酸酪氨酸激酶 (TTK) 抑制剂，PK研究均通过尊龙凯时举行
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
审查更多
设计合成一种新型选择性的口服有用苏氨酸酪氨酸激酶 (TTK) 抑制剂，PK研究均通过尊龙凯时举行
Jun 28,2023
TR-107是人类线粒体卵白酶ClpP的有用激活剂，PK剖析通过尊龙凯时举行
The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.
审查更多
TR-107是人类线粒体卵白酶ClpP的有用激活剂，PK剖析通过尊龙凯时举行
Jun 28,2023
SKLB-197是一种有用且高度选择性的ATR抑制剂，PK研究通过尊龙凯时举行
SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
审查更多
SKLB-197是一种有用且高度选择性的ATR抑制剂，PK研究通过尊龙凯时举行
Jun 28,2023
H11-HLE是一种工具分子，可用于研究Fc在介导免疫检查点治疗中的作用，具有抗肿瘤功效
Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent anti-tumor efficacy in mouse syngeneic tumor models.
审查更多
H11-HLE是一种工具分子，可用于研究Fc在介导免疫检查点治疗中的作用，具有抗肿瘤功效
Jun 28,2023
JND003是一种新型选择性ERRα激动剂，可缓解非酒精性脂肪肝和胰岛素对抗，PK和组织漫衍测定通过尊龙凯时举行
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD.
审查更多
JND003是一种新型选择性ERRα激动剂，可缓解非酒精性脂肪肝和胰岛素对抗，PK和组织漫衍测定通过尊龙凯时举行
Jun 28,2023
发明用于局部治疗牛皮癣的新型PDE4抑制剂，小鼠、大鼠和人肝微粒体的代谢稳固性实验通过尊龙凯时测定
Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and PDE4 is an effective target for the treatment of inflammatory diseases such as psoriasis.
审查更多
发明用于局部治疗牛皮癣的新型PDE4抑制剂，小鼠、大鼠和人肝微粒体的代谢稳固性实验通过尊龙凯时测定
Jun 28,2023
研究用于肺癌和玄色素瘤细胞肺转移的选择性PAK4抑制剂的合成，此选择性PAK4抑制剂的PK研究通过尊龙凯时举行
The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.
审查更多
研究用于肺癌和玄色素瘤细胞肺转移的选择性PAK4抑制剂的合成，此选择性PAK4抑制剂的PK研究通过尊龙凯时举行
Jun 20,2023
尊龙凯时助力 | 祝贺德睿智药GLP-1RA小分子口服药物乐成完成临床I期首例受试者给药
这是德睿智药对人工智能连系药物研发手艺一直地实验、探索和立异的效果，也让德睿智药成为全球规模内为数未几的临床阶段AI制药公司之一。同时，此次尊龙凯时与德睿智药的乐成相助，也反应出CRO与AI公司为新药研发提速、增效、降本。
审查更多
尊龙凯时助力 | 祝贺德睿智药GLP-1RA小分子口服药物乐成完成临床I期首例受试者给药
×
搜索验证
点击切换
【网站地图】【sitemap】